has been widely applied to tumor detection, staging, evaluation of treatment response, and differentiation of malignant tumors from benign lesions in clinical oncology (1, 2) . These applications are based on the increased 18 F-FDG uptake due to enhanced glucose use in most tumors. Recent investigations, including many clinical PET studies, however, have shown that increased 18 F-FDG uptake is not specific to malignant tumors (3) (4) (5) (6) (7) . 18 F-FDG is also taken up in inflammatory lesions, particularly in granulomatous lesions such as sarcoidosis or active inflammatory processes after chemoradiotherapy (3) (4) (5) (6) (7) , making it difficult to differentiate malignant tumors from benign lesions, and is the main source of false-positive 18 F-FDG PET findings in oncology (8) . It has been suggested that these problems may be overcome by multitracer studies using 39-deoxy-39- 18 Ffluorothymidine ( 18 F-FLT) or L-11 C-methionine (8, 9) . 18 F-FLT, a radiolabeled analog of thymidine, has been developed as a PET tracer to image cellular proliferation in vivo (10) . 18 F-FLT is phosphorylated by the enzyme thymidine kinase 1, which leads to intracellular trapping of the tracer. During DNA synthesis, thymidine kinase 1 activity increases almost 10-fold and is thus an accurate reflection of cellular proliferation (8, 11) . On the other hand, 11 C-methionine uptake reflects increased amino acid transport and protein synthesis and is related to cellular proliferation. 11 C-Methionine has been shown to possess a high specificity in tumor detection, tumor delineation, and differentiation of benign from malignant lesions (12, 13) because of the lower uptake of 11 C-methionine than of 18 F-FDG in inflammatory cells (14) (15) (16) . These factors suggest that thymidine or amino acid tracers are potentially more suitable than 18 F-FDG for the differentiation of tumors from inflammatory lesions. However, the uptake of these tracers in granulomatous lesions remains unclarified, mainly because of the lack of suitable animal models. In this regard, we have recently developed a rat model of intramuscular granuloma characterized by epithelioid cell granuloma formation and massive lymphocyte infiltration around the granuloma, histologically similar to sarcoidosis (17) . The rat granuloma showed high 18 F-FDG uptake comparable to that in the tumor, indicating the usefulness of our model for studies of differential diagnosis.
The purpose of this study was to compare the potentials of 18 F-FLT and 11 C-methionine with 18 F-FDG for differentiating malignant tumors from granulomas in the rat model bearing granuloma and tumor.
MATERIALS AND METHODS

Radiopharmaceuticals
18 F-FDG, synthesized by standard procedures, was obtained from Hokkaido University Hospital Cyclotron Facility. L-[methyl- 14 C]methionine (specific activity, 1.48-2.04 GBq/mmol) and [methyl-3 H (N)]-39-fluoro 39-deoxythymidine ( 3 H-FLT) (specific activity, 74-370 GBq/mmol) were purchased from American Radiolabeled Chemicals, Inc., and Moravek Biochemicals Inc.
Animal Studies
All experimental protocols were approved by the Laboratory Animal Care and Use Committee of Hokkaido University. Eightweek-old male Wistar King Aptekman/hok rats (supplied by Japan SLC, Inc.) were used in all experiments. The Mycobacterium bovis bacillus Calmette-Guérin (BCG), a Japanese strain, was grown on Middlebrook 7H11 agar (Difco Laboratories), suspended in phosphatebuffered saline with 0.05% polysorbate 20, and stocked at 280°C. BCG (1 · 10 7 CFU/rat) and allogenic hepatoma cells (KDH-8, 1 · 10 6 cells/rat) were inoculated, respectively, into the left and right calf muscles to generate a rat model bearing both the granuloma and the tumor. Turpentine oil (0.2 mL/rat) and KDH-8 were inoculated, respectively, into the left and right calf muscles to generate a rat model bearing both turpentine oil-induced inflammation and tumor. Figure 1 shows the experimental protocols of the animal studies. At designated periods after inoculation of KDH-8 and BCG or of KDH-8 and turpentine, the rats were kept fasting overnight, anesthetized with pentobarbital (50 mg/kg of body weight, intraperitoneally), and administered an intravenous injection of a mixture of 18 F-FDG (7.4 MBq) and 3 H-FLT (0.185 MBq) or of 18 F-FDG (7.4 MBq) and 14 C-methionine (0.185 MBq). The rats were kept under anesthesia throughout the experiment. To decrease the serum level of endogenous thymidine, the rats were pretreated with thymidine phosphorylase (1,000 U/kg of body weight) 45 min before the injection of a mixture of 18 F-FDG and 3 H-FLT, according to the procedures reported by van Waarde et al. (8) . Sixty minutes after the injection of a mixture of 18 F-FDG and 3 H-FLT or of 18 F-FDG and 14 C-methionine, the animals were sacrificed, and tumor, granuloma, inflammatory tissues, and other organs were excised. The tissues and blood samples were weighed, and 18 F-FDG radioactivity was determined using a g-counter (1480 WIZARD 3$; Wallac Co., Ltd.). The samples were then solubilized with Soluene 350 (Packard Bioscience B.V.), and 3 H-FLT or 14 C-methionine radioactivity was measured using a liquid scintillation counter (LSC-5100; Aloka Co., Ltd.). 18 F-FDG, 3 H-FLT, and 14 C-methionine uptake levels in the tissues were expressed as a differential uptake ratio (DUR) (cpm measured per gram of tissue/cpm injected per gram of body weight) (16) . The lesion (tumor, granuloma, or turpentine-induced inflammatory tissue)-to-muscle (L/M) ratios and the lesion-to-blood (L/B) ratios of 18 F-FDG, 3 H-FLT, and 14 C-methionine uptake were calculated from the DUR value of each tissue (18, 19) . Samples from the tumor, granuloma, and turpentine oil-induced inflammatory tissues were formalin-fixed and paraffinembedded for the subsequent histologic staining. Blood samples for glucose level measurement were obtained immediately before the tracer injection and immediately before sacrifice. Blood glucose FIGURE 1. Experimental protocols of this study. LSC 5 liquid scintillation counter.
level was determined using a biochemical analyzer (MediSense; Dainobot Co., Ltd.).
Histochemical Studies
Formalin-fixed, paraffin-embedded 3-mm-thick sections of tumor, granuloma, and turpentine oil-induced inflammation tissue were stained with hematoxylin and eosin. The immunohistochemical staining of an immune-associated antigen (Ia) was also performed using a monoclonal antibody (mAb) (mouse IgG, MRC OX-6; Oxford Biotechnology Ltd.) that recognizes a monomorphic determinant of rat Ia, MHC class II, present on B lymphocytes, dendritic cells, some macrophages, and certain epithelial cells, as previously described (17) .
Statistical Analysis
All values are expressed as mean 6 SD. The nonparametric Kruskal-Wallis test was used to assess the significance of differences in blood glucose levels among the 4 groups of rats. Statistical analyses were performed using a nonparametric Mann-Whitney U test to evaluate the significance of differences in values between the 2 types of lesions (tumor vs. granuloma or tumor vs. turpentineinduced inflammation). A value of P less than 0.05 was considered significant.
RESULTS
Blood Glucose Level and Histopathologic Findings
There was no statistically significant difference in blood glucose levels among the 4 groups of rats at the times of injection and sacrifice ( Table 1) . The blood glucose levels were within the physiologic range.
In the intramuscular granuloma induced by BCG, the granulomatous lesions showed mature epithelioid cell granuloma formation and massive lymphocyte infiltration around the granuloma ( Fig. 2A) . Immunohistochemical staining also showed the accumulation of Ia-positive macrophages and Ia-positive lymphocytes in the periphery of the granuloma (Fig. 2B ). In the intramuscular tumor induced by KDH-8 cells, massive viable and proliferating cancer cells were observed by hematoxylin-and-eosin staining (Fig. 2C ). In the turpentine-induced inflammatory tissue, massive neutrophil infiltration and ambient connective tissue formation were observed around the site of turpentine oil injection (Fig. 2D) .
Uptake of 18 F-FDG, 3 H-FLT, and 14 C-Methionine 18 F-FDG, 3 H-FLT, and 14 C-methionine uptake in the tumor, granuloma, and turpentine-induced inflammatory tissues are summarized in Figure 3 and Table 2 . Figures 3A and 3B show the tracer uptake levels in rats bearing the tumor and granuloma (groups I and II). The granuloma showed high 18 F-FDG uptake comparable to that in the tumor (group I, 8.18 6 2.40 DUR for granuloma vs. 9.13 6 1.52 DUR for tumor, P 5 NS; group II, 8.43 6 1.45 DUR for granuloma vs. 8.91 6 2.32 DUR for tumor, P 5 NS). 3 H-FLT uptake in the granuloma was also comparable to that in the tumor (group I, 1.98 6 0.70 DUR for granuloma vs. 2.30 6 0.67 DUR for tumor, P 5 NS). Mean 14 C-methionine uptake in the granuloma was significantly lower than that in the tumor (group II, 1.31 6 0.22 DUR for granuloma vs. 2.47 6 0.60 DUR for tumor, P , 0.01). 14 C-Methionine uptake in the granuloma was about 53% of that in the tumor (Fig. 3B) .
In rats bearing the tumor and turpentine oil-induced inflammatory tissue (Figs. 3C and 3D , groups III and IV), the mean 18 F-FDG uptake in the inflammatory tissue was markedly lower than that in the tumor (group III, 2.42 6 0.43 DUR for inflammatory tissue vs. 9.13 6 0.50 DUR for tumor, P , 0.01; group IV, 3.99 6 0.22 DUR for inflammatory tissue vs. 11.14 6 1.03 DUR for tumor, P , 0.05). 3 H-FLT and 14 C-methionine uptake was also significantly lower in the inflammatory tissue than in the tumor (group III, 3 H-FLT, 0.99 6 0.13 DUR for inflammatory tissue vs. 2.66 6 0.13 DUR for tumor, P , 0.01; group IV, 14 C-methionine, 1.77 6 0.18 for inflammatory tissue vs. 2.96 6 0.57 DUR for tumor, P, 0.05).
The L/M and the L/B ratios of 18 F-FDG, 3 H-FLT, and 14 C-methionine uptake are summarized in Table 2 . The mean L/M and L/B ratios of 18 F-FDG and 3 H-FLT uptake in the granuloma were comparable to those in the tumor (group I, P 5 NS). However, the mean L/M and L/B ratios of 14 C-methionine uptake in the granuloma was significantly lower than those in the hepatoma (group II, 3.0 6 0.6 vs. 5.7 6 1.9 for L/M and 1.8 6 0.3 vs. 3.5 6 1.0 for L/B, P , 0.01, respectively). The L/M and L/B ratios of 18 F-FDG, 3 H-FLT, and 14 C-methionine uptake in the turpentine-induced inflammation were markedly lower than those in the tumor (groups III and IV).
DISCUSSION
This study showed that 14 C-methionine uptake in the granuloma was about 50% of that in the tumor (Fig. 3B) , and the difference was significant. In contrast, 18 F-FLT and 18 F-FDG uptake in the granuloma was comparable to that in the tumor. These results suggest the possible usefulness of 11 C-methionine for differentiating malignant tumors from benign lesions, providing a biologic basis for clinical PET studies.
The present results suggest that amino acid tracers are potentially more suitable than 18 F-FDG for the differentiation of tumors from inflammation, including granuloma. Our results are consistent with previous clinical findings that showed that 18 F-FDG uptake is significantly higher than 11 C-methionine uptake in mediastinal bilateral hilar lymphadenopathy with sarcoidosis (20) . On the other hand, to the best of our knowledge, this is the first report on radiolabeled 14 C-methionine uptake in an experimental granuloma, although studies of 14 C-methionine uptake in inflammation induced by intramuscular injections of croton oil and carrageenan (21) have been reported.
It is of great importance to determine the cause of the difference between 11 C-methionine and 18 F-FDG accumulations in granulomas. Cellular uptake of 18 F-FDG in sarcoidosis is considered to be related to inflammatory cell infiltrates, which are composed of lymphocytes, macrophages, and epithelioid cells from monocytes, because 18 F-FDG has been observed in vitro to be accumulated by leukocytes (22, 23) , lymphocytes, and macrophages (24) . An increased 18 F-FDG distribution level was observed mainly in epithelioid cell granulomas by autoradiography, whereas the 14 C-methionine distribution level was low. The activities of granuloma formation and granuloma-associated immune cells may be reflected by the accumulation of 18 F-FDG but not by that of 14 C-methionine, although the detailed mechanisms underlying the accumulation of these tracers in granulomas remain unclarified. As for the accumulation of these tracers in tumors, Kubota et al. (15) have demonstrated by a microautoradiographic study that 14 C-methionine uptake is achieved largely by viable cancer cells, whereas uptake by macrophages and granulation tissues is low, in contrast to 18 F-FDG. An increased 18 F-FDG accumulation in young granulation tissues around a tumor and in macrophages infiltrating the margins of an extensive area of tumor necrosis was observed by microautoradiography using 18 F-FDG and 3 H-deoxyglucose (24) . The distinctive uptake profiles of 18 F-FDG and 11 C-methionine may provide information on the different roles of these tracers in the diagnosis of tumors and inflammation.
This study showed that mean 3 F-FLT uptake in the BCGinduced granuloma was comparable to that in the KDH-8-induced hepatoma, as in the case of 18 F-FDG, although the level of 3 H-FLT uptake was lower than that of 18 F-FDG. Some investigators reported that 18 F-FLT uptake in inflammatory cells is lower than that in tumors, because the mitotic activity of inflammatory cells is lower than that of tumor cells. Van Waarde et al. reported that 18 F-FLT uptake in turpentine-induced inflammation is 32% of that in C6 rat gliomas (8) , suggesting a high tumor specificity of 18 F-FLT (8). Our results for turpentine-induced inflammatory tissue were consistent with previous reports. In contrast, 3 H-FLT uptake in the granuloma was comparable to that in the hepatoma. Clinical studies (25) also showed that a patient with granulomas after radiation and chemotherapy showed increased 18 F-FLT uptake. A patient with nonspecific interstitial pneumonia had a false-positive 18 F-FLT finding (Ki-67 index, 15%) (26) . Inflammatory lung diseases are accompanied by lymphocyte infiltration and involve growth factors that enhance the proliferation of lymphocytes (27) . These findings suggest that 18 F-FLT may accumulate in chronic granulomatous lesions with proliferative inflammation. Our study showed the accumulation of Ia-positive lymphocytes in the periphery of the granuloma (Fig. 2B ) (Ki-67 index, 6.3%), possibly explaining the increased 3 H-FLT uptake in the granulomatous lesions. Thus, our experimental results support previous clinical findings, although detailed investigations, including that of the correlation between the Ki-67 proliferation index and 18 F-FLT distribution in the granuloma and tumor using autoradiography, are required.
Although the usefulness of 11 C-methionine for differentiating malignant tumors from benign lesions was indicated in our experimental models, uptake of 18 F-FLT and 11 Cmethionine by tumor was relatively lower than uptake of 18 F-FDG. An absolute uptake level is also a determinant of the usefulness of radiopharmaceuticals. General tumor detectability might be higher with 18 F-FDG than with others, although several clinical and experimental studies suggested that 18 F-FDG and 11 C-methionine were equally useful in detecting residual or recurrent malignant tumors (16, 28) .
It is important to note the limitations of our study. We measured the biodistribution of 14 C-methionine at 60 min after injection, to avoid technical complications. In clinical settings, however, PET images of 11 C-methionine are usually acquired at 10-30 min after injection, because of the short half-life of 11 C. To investigate whether the biodistribution of 14 C-methionine at early time points provides data similar to those of the present study (at 60 min) in differentiating the tumor from the granuloma, we preliminarily performed biodistribution studies at 5, 15, and 30 min after the 14 Cmethionine injection using the tumor and inflammation models. The findings showed that uptake of 14 C-methionine in the tumor and granuloma plateaued at 15-30 min after the injection. 14 C-Methionine uptake in the granuloma at 15 and 30 min was also significantly lower than that in the tumor-61% and 45%, respectively, of tumor uptake. These results were consistent with the present results, although 14 Cmethionine uptake in the tumor and granuloma at 60 min was lower than that at 15 and 30 min. The biodistribution at early time points supports our results in the present study. It should also be noted that uptake of 14 C-methionine in normal organs was relatively high in our rats. This result may be ascribed to the time point (60 min after injection) at which we performed the 14 C-methionine biodistribution study. Kubota et al. (29) reported that the distribution of 14 C-methionine in abdominal organs including the liver, intestine, and kidney was still increased after 30 min after injection. Another limitation of our study was that only 1 tumor model was used to compare accumulation of the PET pharmaceuticals. Other tumor models should be used to confirm our preliminary results.
CONCLUSION
Our experimental studies demonstrated that 14 C-methionine uptake in the granuloma was significantly lower than that in the tumor, whereas 18 F-FDG and 3 H-FLT were not able to differentiate the granuloma from the tumor. These results suggest that 14 C-methionine should have the potential to accurately differentiate malignant tumors from benign lesions, particularly granulomatous lesions.
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